Payment overview · 2025
General Payments
$420.16
23 reported records · 11 companies
Healthcare provider profile · identity verified
Ronald Michael Lather, MD
Allopathic & Osteopathic Physicians|Internal Medicine · NEW BERN, NC · NPI 1710970660
Verified facts
What the public records show
CMS Open Payments records show Ronald Michael Lather, MD received $420.16 in general payments during 2025 across 23 reported records.
GlaxoSmithKline, LLC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Auvelity, Mounjaro, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Farxiga by this doctor in 2024.
Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Auvelity by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 160 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $85.17 | 20.3% | 5 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $82.21 | 19.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $70.60 | 16.8% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.95 | 13.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $27.40 | 6.5% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.61 | 6.1% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.17 | 3.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $14.93 | 3.5% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $14.92 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.69 | 3.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.51 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $420.16 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $85.17 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $82.21 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $54.95 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $54.95 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $41.78 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $32.13 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $27.40 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $14.92 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Auvelity auvelity |
2025 | Auvelity | 2024 | 67 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 153 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
74 | 14 |
| Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | Auvelity open payments reported associated product |
CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064 |
Auvelity · 2024 Exact normalized brand match · 1 Part D row |
67 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
60 | 50 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
68 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
153 | 34 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
160 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 498 | 109 |
| Levothyroxine Sodium | Levothyroxine Sodium | 437 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 436 | 97 |
| Metoprolol Succinate | Metoprolol Succinate | 371 | 80 |
| Omeprazole | Omeprazole | 343 | 80 |
| Montelukast Sodium | Montelukast Sodium | 288 | 70 |
| Metformin Hcl Er | Metformin Hcl | 281 | 69 |
| Furosemide | Furosemide | 272 | 71 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 66 |
| Spironolactone | Spironolactone | 257 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 241 | 55 |
| Gabapentin | Gabapentin | 227 | 56 |
| Lisinopril | Lisinopril | 211 | 48 |
| Clopidogrel | Clopidogrel Bisulfate | 183 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 176 | 37 |
| Valsartan | Valsartan | 174 | 42 |
| Ozempic | Semaglutide | 160 | 27 |
| Mounjaro | Tirzepatide | 153 | 34 |
| Prednisone | Prednisone | 152 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 34 |
| Simvastatin | Simvastatin | 147 | 40 |
| Trazodone Hcl | Trazodone Hcl | 142 | 34 |
| Potassium Chloride | Potassium Chloride | 141 | 30 |
| Famotidine | Famotidine | 139 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 132 | 25 |
| Losartan Potassium | Losartan Potassium | 132 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 131 | 28 |
| Alprazolam | Alprazolam | 120 | 31 |
| Sertraline Hcl | Sertraline Hcl | 112 | 25 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 111 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 26 |
| Eliquis | Apixaban | 99 | 21 |
| Celecoxib | Celecoxib | 94 | 27 |
| Clonazepam | Clonazepam | 93 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 92 | 16 |
| Tramadol Hcl | Tramadol Hcl | 91 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 90 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 20 |
| Metformin Hcl | Metformin Hcl | 79 | 19 |
| Allopurinol | Allopurinol | 77 | 16 |
| Farxiga | Dapagliflozin Propanediol | 74 | 14 |
| Finasteride | Finasteride | 72 | 16 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 71 | 15 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 70 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 70 | 17 |
| Bupropion Xl | Bupropion Hcl | 69 | 15 |
| Carvedilol | Carvedilol | 69 | 17 |
| Linzess | Linaclotide | 69 | 12 |
| Jardiance | Empagliflozin | 68 | suppressed |
| Auvelity | Dextromethorphan Hbr/Bupropion | 67 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 19 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 60 | 50 |
| Diclofenac Sodium | Diclofenac Sodium | 58 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 56 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 55 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 13 |
| Valacyclovir | Valacyclovir Hcl | 54 | 17 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 22 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Pregabalin | Pregabalin | 49 | suppressed |
| Rybelsus | Semaglutide | 47 | 11 |
| Meloxicam | Meloxicam | 46 | 17 |
| Sucralfate | Sucralfate | 45 | 11 |
| Azithromycin | Azithromycin | 42 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 42 | 16 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 39 | 39 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 12 |
| Olanzapine | Olanzapine | 38 | suppressed |
| Torsemide | Torsemide | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Xarelto | Rivaroxaban | 38 | suppressed |
| Lorazepam | Lorazepam | 37 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Primidone | Primidone | 37 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 36 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 34 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 27 |
| Alprazolam Xr | Alprazolam | 33 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Alprazolam Er | Alprazolam | 32 | suppressed |
| Atenolol | Atenolol | 32 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 31 | suppressed |
| Estradiol | Estradiol | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 24 |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Ketoconazole | Ketoconazole | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 17 |
| Propranolol Hcl Er | Propranolol Hcl | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 26 | 24 |
| Glipizide | Glipizide | 26 | suppressed |
| Hydrocortisone | Hydrocortisone | 26 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 11 |
| Cilostazol | Cilostazol | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 17 |
| Telmisartan | Telmisartan | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 21 |
| Doxepin Hcl | Doxepin Hcl | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Diazepam | Diazepam | 21 | 14 |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Methocarbamol | Methocarbamol | 20 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 19 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 13 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Vraylar | Cariprazine Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Famciclovir | Famciclovir | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $420.16 · 23 records | GlaxoSmithKline, LLC. | Auvelity, BREZTRI, Dexcom G6 Transmitter, FREESTYLE LIBRE 2, MOUNJARO, OTEZLA, REPATHA, REXULTI, TRELEGY ELLIPTA, Wegovy, YUPELRI, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Auvelity play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error